In recent years, GLP-1 receptor agonists have transformed the landscape of obesity and type 2 diabetes management.
Medications such as semaglutide have shown:
- Significant weight loss
- Improved glycaemic control
- Reduced appetite and food intake
For many patients, these medications represent a meaningful step forward. But they also raise an important clinical question: What happens when treatment stops?
GLP-1 receptor agonists work by:
- Enhancing satiety
- Reducing gastric emptying
- Modulating appetite signalling in the brain
More recently, newer agents targeting multiple pathways (GLP-1, GIP, glucagon, and amylin) are being developed to further enhance metabolic outcomes. These therapies represent an important advancement in pharmacological support for metabolic disease. However, they do not address all underlying drivers.
While GLP-1 therapies can support weight reduction, they do not independently resolve:
- Long-standing dietary habits
- Sedentary behaviour patterns
- Sleep disruption
- Chronic stress physiology
- Emotional and environmental triggers for eating
This becomes particularly important in long-term management. Studies have shown that weight regain can occur after discontinuation of GLP-1 therapy, especially when underlying lifestyle factors remain unaddressed.
This highlights a key principle: Medication can initiate change but maintenance requires behaviour change.
Type 2 diabetes and obesity are not driven by a single pathway. They are influenced by:
- Energy intake and expenditure
- Hormonal regulation
- Stress physiology
- Sleep and circadian rhythms
- Behavioural patterns over time
This means that while pharmacotherapy can modify one part of the system, it does not fully address the broader metabolic network.
At Remisi, we view GLP-1 medications as one component within a larger framework of care. Our focus is on addressing the underlying drivers of metabolic dysfunction:
- Insulin resistance
- Visceral adiposity
- Behavioural and environmental triggers
Through structured lifestyle intervention, we aim to support:
- Sustained weight loss
- Improved metabolic flexibility
- Long-term reduction in medication dependency where possible
GLP-1 therapies are not the problem. The challenge arises when:
- Medication is used in isolation
- Behavioural support is not provided
- Long-term sustainability is not considered
The most effective outcomes occur when pharmacological tools are combined with:
- Lifestyle intervention
- Ongoing support
- Structured behaviour change
Because sustainable change does not come from one pathway alone, it comes from addressing the whole system.
References
- Wilding JPH, et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP trials)
- Rubino D, et al. (2021). Weight regain after withdrawal of semaglutide
- Davies MJ, et al. (2021). Management of hyperglycaemia in type 2 diabetes
